Marker Therapeutics, Inc. (MRKR)
1.175
+0.02
(+2.17%)
USD |
NASDAQ |
Sep 14, 12:30
Marker Therapeutics Enterprise Value : 7.252M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 7.252M |
| September 10, 2026 | 8.085M |
| September 09, 2026 | 8.252M |
| September 08, 2026 | 9.419M |
| September 04, 2026 | 7.752M |
| September 03, 2026 | 8.752M |
| September 02, 2026 | 8.919M |
| September 01, 2026 | 9.753M |
| August 31, 2026 | 10.25M |
| August 28, 2026 | 10.92M |
| August 27, 2026 | 12.42M |
| August 26, 2026 | 12.25M |
| August 25, 2026 | 13.42M |
| August 24, 2026 | 13.09M |
| August 21, 2026 | 11.25M |
| August 20, 2026 | 8.419M |
| August 19, 2026 | 9.586M |
| August 18, 2026 | 7.252M |
| August 17, 2026 | 7.418M |
| August 14, 2026 | 7.085M |
| August 13, 2026 | 6.585M |
| August 12, 2026 | 7.418M |
| August 11, 2026 | 6.752M |
| August 10, 2026 | 7.252M |
| August 07, 2026 | 6.752M |
| Date | Value |
|---|---|
| August 06, 2026 | 6.752M |
| August 05, 2026 | 7.085M |
| August 04, 2026 | 8.586M |
| August 03, 2026 | 8.419M |
| July 31, 2026 | 6.918M |
| July 30, 2026 | 6.752M |
| July 29, 2026 | 6.585M |
| July 28, 2026 | 7.752M |
| July 27, 2026 | 8.419M |
| July 24, 2026 | 8.419M |
| July 23, 2026 | 9.252M |
| July 22, 2026 | 8.752M |
| July 21, 2026 | 9.252M |
| July 20, 2026 | 9.419M |
| July 17, 2026 | 9.920M |
| July 16, 2026 | 10.42M |
| July 15, 2026 | 11.59M |
| July 14, 2026 | 12.09M |
| July 13, 2026 | 12.42M |
| July 10, 2026 | 13.25M |
| July 09, 2026 | 14.42M |
| July 08, 2026 | 14.92M |
| July 07, 2026 | 16.09M |
| July 06, 2026 | 12.75M |
| July 02, 2026 | 12.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ironwood Pharmaceuticals, Inc. | 991.92M |
| SELLAS Life Sciences Group, Inc. | 2.193B |
| Rezolute, Inc. | 287.20M |
| Krystal Biotech, Inc. | 9.433B |
| Larimar Therapeutics, Inc. | 257.87M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.826M |
| Total Expenses (Quarterly) | 1.826M |
| EPS Diluted (Quarterly) | -0.0946 |
| Earnings Yield | -40.91% |
| Normalized Earnings Yield | -40.90 |